These findings have prompted a reassessment of the drugs risk-benefit profile by both medical professionals and patients
The combination of GLP-1, GIP, and glucagon receptor activity creates a complex but effective glucose-lowering effect
It was well tolerated at lower doses by chondrocytes, meaning there was no significant difference in cellular activity and cell proliferation was not affected [47]
Previously, a randomized controlled trial demonstrated that the efficacy of PEG-Loxenatide in patients with mild-to-moderate DKD was comparable to that of the first-line SGLT2 inhibitors, such as Dapagliflozin, with an additional benefit of improved lipid levels [5]
A reasonable long-term target for many adults is about 25 to 35 grams of fiber daily, but personal needs vary
For more on safe access and prescription, see Getting GLP-1 prescriptions safely